Figure 5 Normal somatostatin receptor scintigram

Nov 19, 2014

30 likes | 183 Views

Figure 5 Normal somatostatin receptor scintigram. van Essen, M. et al. (2013) Neuroendocrine tumours: the role of imaging for diagnosis and therapy Nat. Rev. Endocrinol. doi:10.1038/nrendo.2013.246.

Share Presentation

Embed Code

Link

endocrinol
1038 nrendo
van essen
doi 10
2013 neuroendocrine tumours

dieter-eaton

Download Presentation

Figure 5 Normal somatostatin receptor scintigram

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

Figure 5 Normal somatostatin receptor scintigram van Essen, M. et al.(2013) Neuroendocrine tumours: the role of imaging for diagnosis and therapy Nat. Rev. Endocrinol. doi:10.1038/nrendo.2013.246

Figure 5-60

Figure 5-60. Page 122. EcoRI. Tetracycline Resistance. Ampicillin Resistance. PstI. HindIII. +. +. +. +. +. Origin of Replication. A plasmid. Figure 5-43 The pUC18 cloning vector. Page 106. Figure 5-46 Construction of a recombinant DNA molecule. Page 108.

823 views • 54 slides

Supplementary figure 5

A. GBT-B1 (^Gal4-VP16). B. GBT-B2 (^Gal4-FF). Supplementary Figure 1. D. Supplementary figure 5.

135 views • 1 slides

Figure 5

Figure 1. Figure 4. Figure 3. Figure 5 Potential Growth from Establishing a MUHC PCP Relationship with Patients without a Designated PCP. Figure 2.

182 views • 1 slides

Supplementary Figure 5

Supplementary Figure 5.

63 views • 1 slides

Figure 5-22

Figure 5-22. Digital to Analog Encoding. 3 Characteristics of a sine wave Amplitude Frequency Phase 3 Mechanisms for Modulating Digital Data into Analog Signal ASK FSK PSK. Figure 5-23. Bit Rate and Baud Rate. Bit rate number of bits transmitted during 1 second Baud rate

1.1k views • 32 slides

Supplemental Figure 5

Supplemental Figure 5. A. MTLn3 GFP-CXCL12. MTLn3 GFP-pQCXIP. C. B. ***. CXCR4. IgG. % of max. BMM Chemotaxis to CXCL12. % of max. CXCR4-PE. CXCR4-PE. IgG. CXCR4. B.

118 views • 1 slides

Supplemental Figure 5

Trastuzumab-treated. Control-treated. A. MDA-MB-453. 14.2%. 10.7%. DEAB-inhibited. DEAB-inhibited. B. JIMT-1. 5.2%. 5.4%. DEAB-inhibited. DEAB-inhibited. C. Sum159-HER2. 7.1%. 36%. DEAB-inhibited. DEAB-inhibited. Trastuzumab-treated. Control-treated. D. Supplemental Figure 5.

134 views • 1 slides

Figure 2 . Domain organization of the Notch Receptor.

Post DTT. Post DTT. LNRB_orig. HD Domain. LNRB_int. LNR Domain. LNRB_delBC. LNRB_delAB. B. A. Disulfide Connectivity. LNRB_short. A. B. C. 3:6. 2:4. 1:5. A. B. CaCl 2. CaCl 2. A. ZnCl 2. MgCl 2. LNRB_delBC. Mutant LNRB_delBC. LNRB_orig. LNRB_int. Mutant LNRB_orig.

131 views • 1 slides

Figure 5

2° ab alone. GPBAR1+ LPMC. Control TNBS + vehicle TNBS + Ciprofloxacin. A B E. Control TNBS TNBS

151 views • 1 slides

Supplemental Figure 5

Supplemental Figure 5.

79 views • 1 slides

Figure 5

Figure 5. Anna C. Seale. (2013) 74 , 00-00. doi:10.1038/pr.2013.207.

147 views • 1 slides

Suppl Figure 5

Suppl Figure 5. WT ctl1. WT ctl1. conditional defect. NO 3 - , Cl - , sucrose Hermans et al . (2010). Low, moderate NO 3 -. High NO 3 -. Endogenous content/production ABA ↓ C K ↑ C 2 H 4 ↑↑ Exogenous supply ABA induces the arm phenotype

152 views • 1 slides

Figure 5-16

Figure 5-16. Analog to Digital Encoding.  The McGraw-Hill Companies, Inc., 1998. WCB/McGraw-Hill. Figure 5-17. PAM.  The McGraw-Hill Companies, Inc., 1998. WCB/McGraw-Hill. Figure 5-18. Quantized PAM Signal.  The McGraw-Hill Companies, Inc., 1998. WCB/McGraw-Hill. Figure 5-19.

451 views • 27 slides

Supplemental Figure 5

Supplemental Figure 5. p <0.05. p =0.05. a. b. p <0.05. p <0.05. p <0.05. p <0.05. c. Muscle. d. Liver. + - + - UCP3. p <0.01. UCP3. SDH. p <0.05.

85 views • 1 slides

Supplementary Figure 5

Supplementary Figure 5. A. 6h 12h 18h 24h. Rab 3B myosin heavy chain 7 putative cold shock domain protein A myosin heavy chain 4 myosin heavy chain 3 actinin alpha 2 E-cadherin. 0.2. B. 1.0. CONTROL 24 h. BaP 24 h. 5.0. (a). (b).

101 views • 1 slides

Supplementary Figure 5

A. C. B. Supplementary Figure 5.

62 views • 1 slides

Figure 5

Figure 5.

81 views • 1 slides

Figure 5-15

Figure 5-15. Analog to Digital Encoding.  The McGraw-Hill Companies, Inc., 1998. WCB/McGraw-Hill. Figure 5-16. PAM.  The McGraw-Hill Companies, Inc., 1998. WCB/McGraw-Hill. Figure 5-17. Quantized PAM Signal.  The McGraw-Hill Companies, Inc., 1998. WCB/McGraw-Hill. Figure 5-18.

351 views • 27 slides

Supplementary Figure 5

Supplementary Figure 5. a. T80. HEY. ATG5 shRNA H2-1 + FAC. ATG5 shRNA H2-2 + FAC. ATG5 shRNA H2-1 + FAC. ATG5 shRNA H2-2 + FAC. ATG5 shRNA H2-1. ATG5 shRNA H2-2. Control-1 + FAC. Control-2 + FAC. ATG5 shRNA H2-1. ATG5 shRNA H2-2. Control-1 + FAC. Control-2 + FAC. Control-1.

102 views • 1 slides

Figure 5

b. a. Figure 5. c.

79 views • 1 slides

Somatostatin Receptor Type 4 (SSTR4) H1 2017 Therapeutics Review Featuring Drug Profiles Analysis

According to the recently published report 'Somatostatin Receptor Type 4 (SSTR4) - Pipeline Review, H1 2017'; Somatostatin Receptor Type 4 (SSTR4) pipeline Target constitutes close to 6 molecules.

107 views • 4 slides

Electrocardiography – Normal 5

Electrocardiography – Normal 5. Faisal I. Mohammed, MD, PhD. Objectives. Describe the different “waves” in a normal electrocardiogram. Recall the normal P-R and Q-T interval time of the QRS wave. Distinguish the difference in depolarization and repolarization waves.

412 views • 38 slides

More Related